Shares of Quantum Biopharma Ltd. (NASDAQ:QNTM - Get Free Report) rose 3.8% during mid-day trading on Friday . The company traded as high as $23.73 and last traded at $23.37. Approximately 106,783 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 892,441 shares. The stock had previously closed at $22.51.
Wall Street Analyst Weigh In
QNTM has been the subject of a number of recent research reports. Singular Research upgraded Quantum Biopharma to a "moderate buy" rating in a research note on Wednesday, June 18th. Wall Street Zen upgraded Quantum Biopharma from a "sell" rating to a "hold" rating in a research note on Saturday, June 7th.
Get Our Latest Report on QNTM
Quantum Biopharma Trading Up 3.8%
The firm has a market capitalization of $68.01 million, a price-to-earnings ratio of -1.46 and a beta of 0.67. The company has a fifty day moving average price of $17.48 and a two-hundred day moving average price of $10.07.
Quantum Biopharma (NASDAQ:QNTM - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($1.41) EPS for the quarter, missing analysts' consensus estimates of ($0.37) by ($1.04). The company had revenue of $2.09 million during the quarter, compared to analysts' expectations of $2.09 million. As a group, equities research analysts expect that Quantum Biopharma Ltd. will post -3.27 earnings per share for the current year.
Institutional Trading of Quantum Biopharma
A hedge fund recently raised its stake in Quantum Biopharma stock. AdvisorShares Investments LLC boosted its holdings in Quantum Biopharma Ltd. (NASDAQ:QNTM - Free Report) by 163.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 69,078 shares of the company's stock after buying an additional 42,845 shares during the quarter. AdvisorShares Investments LLC owned approximately 3.60% of Quantum Biopharma worth $254,000 at the end of the most recent quarter. 1.24% of the stock is currently owned by hedge funds and other institutional investors.
Quantum Biopharma Company Profile
(
Get Free Report)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Featured Articles
Before you consider Quantum Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quantum Biopharma wasn't on the list.
While Quantum Biopharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
